Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive Results

11/25/2021 | 12:10am EST

New pediatric formulation of Praziquantel, which Astellas Pharma Inc. ("Astellas") provided its formulation technology and has been developed under the initiative of Merck together with its consortium partners, has now been completed its pivotal Phase 3 trial. The favorable results of this clinical trial allow the program to progress towards regulatory file submission to the European Medicines Agency (EMA).

The existing praziquantel tablet is the "standard of care" treatment for schistosomiasis, which is one of the most prevalent parasitic diseases in developing countries. As it is not suitable for the treatment of pre-school aged children because of its large size and bitter taste, those children have been untreated.

To solve these problems, the new pediatric formulation has been developed with Astellas' formulation technology. This new formulation is a smaller and orally dispersible tablet. It has reduced bitterness that can be taken with or without water. The pediatric formulation has also been designed for production using simple manufacturing processes and yielding tablets that are stable even in hot and humid tropical climates. To facilitate production of materials for clinical trials and help build local pharmaceutical manufacturing capabilities for future supplies, Astellas has transferred to consortium partners in Germany and Brazil the technology and expertise needed to develop the pediatric formulations and produce the tablets.

This activity is funded by the Global Health Innovative Technology Fund (GHIT Fund) and The European & Developing Countries Clinical Trials Partnership (EDCTP).

For details on the completion of this Phase 3 clinical trial, please see the Press Release from PEDIATRIC PRAZIQUANTEL CONSORTIUM.

For more information on Astellas' contribution for the development of the Praziquantel, please see (https://www.astellas.com/en/sustainability/development-of-pediatric-formulation-for-schistosomiasis)

Disclaimer

Astellas Pharma Inc. published this content on 25 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2021 05:09:02 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
01/19Essa Pharma Commences Dosing in Phase 1/2 Clinical Trial of Prostate Cancer Combo Thera..
MT
01/16Glenmark Pharmaceuticals Unit Gets US FDA's Approval for Regadenoson Injection
MT
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
01/10Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System M..
MT
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
MT
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
DJ
01/07Modalis Announces Termination of Research Collaboration on MDL-204
CI
01/06Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
AQ
2021Japanese shares end higher on Wall St boost, airlines shine
RE
2021Japanese shares track Wall Street higher, Omicron concerns weigh
RE
More news
Financials
Sales 2022 1 328 B 11 646 M 11 646 M
Net income 2022 183 B 1 609 M 1 609 M
Net cash 2022 380 B 3 333 M 3 333 M
P/E ratio 2022 19,4x
Yield 2022 2,63%
Capitalization 3 526 B 30 864 M 30 930 M
EV / Sales 2022 2,37x
EV / Sales 2023 2,09x
Nbr of Employees 15 455
Free-Float -
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 903,00 JPY
Average target price 2 451,67 JPY
Spread / Average Target 28,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.1.23%30 709
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
ABBVIE INC.-0.14%239 035
NOVO NORDISK A/S-12.67%223 059